Pancreatic Cancer: Research-driven Clinical Progress Examined at AACR Special Conference
With a five-year survival rate of only 12.5%, any progress toward new therapeutic approaches for pancreatic cancer is welcomed...
Tag: Cancer immunotherapy
With a five-year survival rate of only 12.5%, any progress toward new therapeutic approaches for pancreatic cancer is welcomed...
The use of immunotherapy in the treatment of cancer has dramatically increased in the five years since the U.S....
Since 2011, immunotherapy has emerged as an exciting new approach to cancer treatment that is yielding unprecedented, durable responses...
Last week, the U.S. Food and Drug Administration (FDA) announced that it had approved expanding the use of the...
A hot topic in the field of cancer immunotherapy is: How do some cancers that initially respond to immune...
The next step in trying to increase the proportion of patients who respond to these therapies, therefore, is to...
Experts identify opportunities and challenges facing cancer researchers in 2017.
Earlier this week, the U.S. Food and Drug Association (FDA) announced it had approved the immunotherapeutic atezolizumab (Tecentriq) for...
A study published recently in the AACR’s journal Cancer Immunology Research describes an important update to the CAR T-cell...
New imaging system can help surgeons get more cancer out; Presurgery chemo can make ovarian cancer responsive to immunotherapy...